UNICHEM LABORATORIES LTD.

Unichem Laboratories Ltd has informed BSE that a meeting of its Board of Directors is scheduled for Wednesday, November 4, 2026. The primary agenda item is to consider and approve the Unaudited Financial Results (Consolidated and Standalone) for the second quarter and six months ended September 30, 2026, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Unichem Laboratories Ltd announced that its Goa formulation facility underwent an inspection by the United States Food and Drug Administration (USFDA) from September 21st to September 26th, 2026. The inspection concluded with five observations, primarily related to procedural enhancements. The company is committed to providing a comprehensive response to the USFDA within the stipulated 15-day period. This development is a routine regulatory process for pharmaceutical facilities operating internationally.

Unichem Laboratories Ltd has announced the closure of its trading window for designated persons, directors, insiders, and their immediate relatives. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut from October 1, 2026, until 48 hours after the company publicly announces its unaudited financial results for the quarter and half-year ended September 30, 2026. This measure is standard practice to prevent potential insider trading ahead of financial disclosures.

Unichem Laboratories Ltd has received an Order-In-Appeal from the Commissioner (Appeals Thane) concerning a cross-charge of common services. The order disallowed a penalty of ₹87,07,09,556 and interest liability of ₹6,58,76,590 under the CGST Act, 2017. The company disputes the alleged violation of delayed tax payment. Unichem Laboratories stated that there will be no material impact on its financial or operational activities and plans to file an appeal within the prescribed timelines, based on legal advice.

Unichem Laboratories Ltd announced the extension of the exercise period for vested options under its Employee Stock Option Scheme 2018. The Nomination and Remuneration Committee (NRC) approved the extension via circular resolution on September 11, 2026. This affects the first and second tranches of vested options, with the exercise period now extended to March 31, 2027, from the previous date of September 30, 2026. The first tranche comprises 250,000 options vesting on July 1, 2024, and the second tranche includes 125,000 options vesting on May 1, 2025. All other terms and conditions of the granted options remain unchanged.

Unichem Laboratories Ltd has responded to an exchange query regarding a significant increase in its securities' trading volume. The company stated that the surge is purely market-driven and that it has no further comments to offer. Unichem Laboratories affirmed its commitment to making timely disclosures of all material events and information as per SEBI (LODR) Regulations, 2015, and will continue to comply with its disclosure obligations.

Unichem Laboratories Ltd announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported a consolidated profit after tax (PAT) of ₹41.47 Crores, a significant increase from the previous year's corresponding quarter. Total income for the quarter stood at ₹648.23 Crores. The Board of Directors approved these financial statements, which were also accompanied by the auditors' limited review report. The results will be available on the company's website and stock exchange portals.

Unichem Laboratories' consolidated (primary) results show a clear year-on-year turnaround: Q1 FY27 revenue rose 20.1% YoY to ₹632.62 Cr (from ₹526.60 Cr) and net profit swung to ₹41.47 Cr from a ₹10.47 Cr loss in Q1 FY26. Sequentially the print was also strong — revenue up 10.0% and PAT up ~280% over Q4 FY26's ₹575.12 Cr / ₹10.91 Cr — though that base included a ₹12.36 Cr one-off employee-benefit provision (New Labour Codes) that is absent this quarter, so part of the QoQ jump is a clean-base effect rather than fresh momentum. The margin story is the real driver: consolidated NPM expanded to 6.4% of total income from -2.0% a year ago and 1.8% last quarter, and pre-exceptional PBT margin swung to +7.7% of revenue from -1.7% YoY. The bridge is cost of materials consumed falling to 30.0% of revenue (₹190.02 Cr) from 41.3% (₹217.48 Cr) a year ago, even as revenue grew — a meaningful raw-material/mix improvement — partly offset by other expenses rising 12.6% YoY to ₹170.78 Cr. Employee costs were roughly flat (₹103.31 Cr vs ₹107.42 Cr YoY). The basis matters here: standalone (India) revenue actually declined 4.7% YoY to ₹366.27 Cr, and standalone PAT of ₹5.53 Cr was entirely a function of ₹16.72 Cr other income — on core operations alone, standalone expenses (₹375.61 Cr) exceeded revenue. The consolidated beat is thus concentrated overseas: auditors note the US subsidiary and UK-based Niche Generics together booked ₹470.28 Cr of revenue and ₹12.39 Cr of PAT this quarter, reviewed by other (non-principal) auditors. We have no formal management guidance on record and no prior concall read to check this print against, and no solid Street consensus for this specific quarter turned up in search — so vsGuidance and vsStreet are both marked unknown rather than assumed. Company events this quarter were largely procedural (AGM notice, board meeting notice) aside from a partial GSTR TRAN-1 credit allowance from CGST appellate authorities on 29th July 2026, whose P&L impact, if any, isn't quantified in this filing. Going forward, the print sets up three things to track: whether the standalone (domestic) business returns to organic profitability without leaning on other income, whether the outsized overseas contribution (₹470.28 Cr) is a sustainable run-rate or a one-quarter spike, and whether the raw-material cost improvement (30.0% of revenue) holds as input costs and product mix normalize.

Unichem Laboratories Ltd has received a partial decision from the Additional Commissioner, CGST (Appeals), Dehradun, regarding its appeal for GSTR TRAN 1 credit. The appeal was filed against an order disallowing a credit of ₹73,02,757/-. The appellate authority has now allowed a portion of the credit, raising a demand of ₹10,59,354/- plus interest. The company stated that this will have no material impact on its financial or operational activities and plans to take appropriate steps, including a potential further appeal.

Unichem Laboratories Ltd announced that its Board of Directors will convene on Tuesday, August 11, 2026. The primary agenda item for this meeting is to consider and approve the Unaudited Financial Results, both consolidated and standalone, for the quarter that concluded on June 30, 2026. This meeting is a routine procedural step for the company to finalize and disclose its quarterly financial performance.